LMNX has been the subject of a number of other research reports. Zacks Investment Research cut Luminex Corporation from a strong-buy rating to a hold rating in a research report on Tuesday, July 4th. ValuEngine cut Luminex Corporation from a hold rating to a sell rating in a research report on Saturday, July 8th. BidaskClub cut Luminex Corporation from a hold rating to a sell rating in a research report on Friday, July 28th. Finally, Jefferies Group LLC reissued a hold rating and issued a $21.00 price objective on shares of Luminex Corporation in a research report on Friday, October 20th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $20.00.
Shares of Luminex Corporation (NASDAQ:LMNX) opened at $21.47 on Wednesday. The firm has a market cap of $941.00 million, a PE ratio of 36.83, a P/E/G ratio of 3.29 and a beta of 0.18.
Luminex Corporation (NASDAQ:LMNX) last announced its earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.06. The business had revenue of $74.14 million for the quarter, compared to analysts’ expectations of $74.38 million. Luminex Corporation had a return on equity of 6.01% and a net margin of 9.52%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.21 EPS. equities analysts forecast that Luminex Corporation will post 0.4 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 13th. Shareholders of record on Friday, September 22nd were given a dividend of $0.06 per share. The ex-dividend date was Thursday, September 21st. This represents a $0.24 dividend on an annualized basis and a yield of 1.12%. Luminex Corporation’s dividend payout ratio is currently 36.36%.
In other Luminex Corporation news, Director Robert J. Cresci sold 19,631 shares of Luminex Corporation stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $18.98, for a total transaction of $372,596.38. Following the completion of the sale, the director now owns 260,358 shares of the company’s stock, valued at approximately $4,941,594.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of LMNX. Karp Capital Management Corp acquired a new stake in Luminex Corporation during the 1st quarter worth about $225,000. JPMorgan Chase & Co. lifted its position in Luminex Corporation by 820.6% during the 1st quarter. JPMorgan Chase & Co. now owns 38,426 shares of the medical instruments supplier’s stock worth $706,000 after acquiring an additional 34,252 shares during the period. OppenheimerFunds Inc. acquired a new stake in Luminex Corporation during the 1st quarter worth about $218,000. Teachers Advisors LLC lifted its position in Luminex Corporation by 4.7% during the 1st quarter. Teachers Advisors LLC now owns 87,489 shares of the medical instruments supplier’s stock worth $1,607,000 after acquiring an additional 3,950 shares during the period. Finally, Vanguard Group Inc. lifted its position in Luminex Corporation by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 3,446,060 shares of the medical instruments supplier’s stock worth $63,304,000 after acquiring an additional 144,813 shares during the period. 77.89% of the stock is owned by institutional investors.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
What are top analysts saying about Luminex Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Luminex Corporation and related companies.